Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 12/20 | 0.64 |
| ▸ | APP | P05067 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TXN | P10599 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1391414 | 0.87 | APP (0.78) | KCNH3APPLMNASLC2A1L3MBTL1 | |
| SCHEMBL1391842 | 0.84 | KCNH3 (0.65) | KCNH3APPTXN | |
| SCHEMBL10247473 | 0.83 | APP (0.56) | KCNH3APPMAPTKMT2AMEN1 | |
| SCHEMBL2874930 | 0.83 | NFKB1 (0.65) | APPMAPTLMNAPOLBSMN1; SMN2 | |
| SCHEMBL17091524 | 0.83 | KCNH3 (0.64) | KCNH3MAPTKMT2AMEN1TXN | |
| SCHEMBL8524478 | 0.82 | MEN1 (0.71) | APPMAPTLMNAPOLBSMN1; SMN2 | |
| SCHEMBL1923791 | 0.80 | KCNH3 (0.97) | KCNH3 | |
| SCHEMBL1391588 | 0.80 | KCNH3 (0.55) | KCNH3APPMAPTLMNAPOLB | |
| SCHEMBL1390998 | 0.80 | KCNH3 (0.59) | KCNH3MAPTKMT2AMEN1TXN | |
| SCHEMBL10245089 | 0.79 | APP (0.67) | KCNH3APPMAPTLMNASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2231624-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | Progenics Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | KCNH3 3535/4885APP 4146/4885MAPT 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.